These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37760554)

  • 1. Immunohistochemical Evaluation of the Expression of Specific Membrane Antigens in Patients with Pancreatic Ductal Adenocarcinoma.
    Nicoletti A; Vitale F; Quero G; Paratore M; Fiorillo C; Negri M; Carlino A; Inzani F; Gasbarrini A; Alfieri S; Zileri Dal Verme L
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
    Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
    Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
    [No Abstract]   [Full Text] [Related]  

  • 3. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
    Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
    PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Annexin A10 expression is correlated with poor prognosis in pancreatic ductal adenocarcinoma.
    Ishikawa A; Kuraoka K; Zaitsu J; Saito A; Yamaguchi A; Kuwai T; Sudo T; Hadano N; Tashiro H; Taniyama K; Yasuif W
    Histol Histopathol; 2022 Mar; 37(3):243-250. PubMed ID: 34821375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and therapeutic implications of a novel immunohistochemical panel detecting duodenal mucosal invasion by pancreatic ductal adenocarcinoma.
    Sopha SC; Gopal P; Merchant NB; Revetta FL; Gold DV; Washington K; Shi C
    Int J Clin Exp Pathol; 2013; 6(11):2476-86. PubMed ID: 24228110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrant methylation of MUC1 and MUC4 promoters are potential prognostic biomarkers for pancreatic ductal adenocarcinomas.
    Yokoyama S; Higashi M; Kitamoto S; Oeldorf M; Knippschild U; Kornmann M; Maemura K; Kurahara H; Wiest E; Hamada T; Kitazono I; Goto Y; Tasaki T; Hiraki T; Hatanaka K; Mataki Y; Taguchi H; Hashimoto S; Batra SK; Tanimoto A; Yonezawa S; Hollingsworth MA
    Oncotarget; 2016 Jul; 7(27):42553-42565. PubMed ID: 27283771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semiquantitative immunohistochemistry for mucin (MUC1, MUC2, MUC3, MUC4, MUC5AC, and MUC6) profiling of pancreatic ductal cell adenocarcinoma improves diagnostic and prognostic performance.
    Sierzega M; Młynarski D; Tomaszewska R; Kulig J
    Histopathology; 2016 Oct; 69(4):582-91. PubMed ID: 27165582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis of pancreatic neoplasms using a novel method of DNA methylation analysis of mucin expression in pancreatic juice.
    Yokoyama S; Kitamoto S; Higashi M; Goto Y; Hara T; Ikebe D; Yamaguchi T; Arisaka Y; Niihara T; Nishimata H; Tanaka S; Takaori K; Batra SK; Yonezawa S
    PLoS One; 2014; 9(4):e93760. PubMed ID: 24714692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
    Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
    Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.
    Padden J; Ahrens M; Kälsch J; Bertram S; Megger DA; Bracht T; Eisenacher M; Kocabayoglu P; Meyer HE; Sipos B; Baba HA; Sitek B
    Mol Cell Proteomics; 2016 Mar; 15(3):1072-82. PubMed ID: 26644413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reevaluation and identification of the best immunohistochemical panel (pVHL, Maspin, S100P, IMP-3) for ductal adenocarcinoma of the pancreas.
    Liu H; Shi J; Anandan V; Wang HL; Diehl D; Blansfield J; Gerhard G; Lin F
    Arch Pathol Lab Med; 2012 Jun; 136(6):601-9. PubMed ID: 22646265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma.
    Thompson CM; Cannon A; West S; Ghersi D; Atri P; Bhatia R; Smith L; Rachagani S; Wichman C; Kumar S; Batra SK
    Clin Cancer Res; 2021 Dec; 27(24):6787-6799. PubMed ID: 34615717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125).
    Chauhan SC; Singh AP; Ruiz F; Johansson SL; Jain M; Smith LM; Moniaux N; Batra SK
    Mod Pathol; 2006 Oct; 19(10):1386-94. PubMed ID: 16880776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annexin A10 optimally differentiates between intrahepatic cholangiocarcinoma and hepatic metastases of pancreatic ductal adenocarcinoma: a comparative study of immunohistochemical markers and panels.
    Kälsch J; Padden J; Bertram S; Pott LL; Reis H; Westerwick D; Schaefer CM; Sowa JP; Möllmann D; Fingas C; Dechȇne A; Sitek B; Eisenacher M; Canbay A; Ahrens M; Baba HA
    Virchows Arch; 2017 May; 470(5):537-543. PubMed ID: 28357490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical Mucin Expression Predicts Worse Overall Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Qian Y; Gong Y; Liu Y; Chen Y; Wang R; Dai Z; Zou X; Tasiheng Y; Luo G; Lin X; Wang X; Cheng H; Yu X; Liu C
    J Immunol Res; 2022; 2022():7353572. PubMed ID: 35910854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Expression Profile and Textural Characteristics of C595-Reactive MUC1 in Pancreatic Ductal Adenocarcinoma for Targeted Radionuclide Therapy.
    Hull A; Li Y; Bartholomeusz D; Hsieh W; Escarbe S; Ruszkiewicz A; Bezak E
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33379259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
    Montemagno C; Cassim S; Pouyssegur J; Broisat A; Pagès G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
    Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
    Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered expression of transmembrane mucins, MUC1 and MUC4, in bladder cancer: pathological implications in diagnosis.
    Kaur S; Momi N; Chakraborty S; Wagner DG; Horn AJ; Lele SM; Theodorescu D; Batra SK
    PLoS One; 2014; 9(3):e92742. PubMed ID: 24671186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of intratumoral fluid-containing area by magnetic resonance imaging to predict prognosis in patients with pancreatic ductal adenocarcinoma after curative resection.
    Kim H; Kim DH; Song IH; Youn SY; Kim B; Oh SN; Choi JI; Rha SE
    Eur Radiol; 2022 Apr; 32(4):2518-2528. PubMed ID: 34671833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.